This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Rene Hoet, PhD
Chief Scientific Officer at Imcheck Therapeutics

Profile

René Hoet joint Imcheck Therapeutics Oct. 2018 as Chief Scientific officer. Before joining ImCheck, René spent 8 years at Bayer AG as Vice President Biologics Research, where his team was responsible for antibody lead discovery and optimization. Between 2008-2010, he was a member of the management team at Genmab and as Sr. Director Research led the team Product Related Research, Scientific Communication & Translational Research. Together with his team, he ran the antibody discovery programs and actively supported Genmab’s clinical antibody programs.

René started his industrial career at Target Quest (acquired by Dyax in 1999) where his last position was Vice President Research and Operational Manager of Dyax SA. He was the driving force for internal antibody lead discovery as well as external collaborations and supported the out-licensing of Dyax’ antibody phage libraries. From these libraries, 4 antibodies have been approved by the FDA & EMA and over 10 antibodies from varies companies are currently in clinical trials.

René Hoet is also Professor Biopharmaceutics at the University of Maastricht, Netherlands, guiding researchers to use antibodies to bridge the gap between academic research and pharmaceutical applications.

Agenda Sessions

  • Development of a Next Generation Anti-Cancer Immunotherapy: A Humanized anti-BTN3A Antibody that Activates V9V2 T cells

    00:35
  • LIVE Moderated Panel Discussion and Q&A Including Audience Interaction with Speakers from On-Demand SESSION #7: CELL ENGAGERS FOR THE INNATE IMMUNE SYSTEM - To prepare for this discussion/Q&A, attendees should view the presentations from Session #7 in the Watch On-Demand Sessions Tab prior to this session

    11:15